Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 2;23(15):8600.
doi: 10.3390/ijms23158600.

A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies

Haley Newman  1   2 , David T Teachey  1   2
Affiliations
Review

A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies

Haley Newman et al. Int J Mol Sci. .

Abstract

Immunotherapy has transformed the treatment of hematologic malignancies in the past two decades. The treatment of acute lymphoblastic leukemia (ALL), in particular, has been highly impacted by multiple novel immunotherapies. For pediatric patients with T-cell malignancies, translating immunotherapies has proved more challenging due to the complexities of fratricide, risk of product contamination with malignant cells, and concerns over T-cell aplasia. Despite these hurdles, many creative and promising strategies are on the horizon. We review challenges in the development of immunotherapy for T-cell malignancies, strategies to overcome these challenges, as well as therapies currently being investigated and starting to reach the clinic. Immunotherapy will hopefully successfully treat patients with relapsed and refractory T-cell malignancies and may someday be incorporated in up-front protocols in order to prevent relapses.

Keywords: CAR T-cell therapy; T-cell acute lymphoblastic leukemia; anaplastic large cell lymphoma; immunotherapy; pediatric cancer.

PubMed Disclaimer

Conflict of interest statement

DTT serves on advisory boards for Sobi, Janssen, and BEAM Therapeutics. DTT receives research funding from BEAM Therapeutics and NeoImmune Tech. DTT has patents pending on CD38 CAR-T cells for hematologic malignancies and biomarkers for cytokine release syndrome.

References

    1. Taylor R.P., Lindorfer M.A. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies. Semin. Immunol. 2016;28:309–316. doi: 10.1016/j.smim.2016.03.003. - DOI - PubMed
    1. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 2005;23:1147–1157. doi: 10.1038/nbt1137. - DOI - PubMed
    1. Oflazoglu E., Audoly L.P. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. mAbs. 2010;2:14–19. doi: 10.4161/mabs.2.1.10789. - DOI - PMC - PubMed
    1. Salles G., Barrett M., Foa R., Maurer J., O’Brien S., Valente N., Wenger M., Maloney D.G. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv. Ther. 2017;34:2232–2273. doi: 10.1007/s12325-017-0612-x. - DOI - PMC - PubMed
    1. Maury S., Chevret S., Thomas X., Heim D., Leguay T., Huguet F., Chevallier P., Hunault M., Boissel N., Escoffre-Barbe M., et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N. Engl. J. Med. 2016;375:1044–1053. doi: 10.1056/NEJMoa1605085. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources